Home > Quotes > NITE

Nightstar Therapeutics plc American Depositary Shares Quote & Summary Data

Get NITE Alerts
*Delayed - data as of Dec. 11, 2017 10:50 ET  -  Find a broker to begin trading NITE now
Industry: Health Care
Community Rating:
View:    NITE Real Time
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
Company Headlines Press Releases Market Stream
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Intraday Chart

Shares Traded

Trading Range

The current last sale of $16.25 is 11.61% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 16.604 $ 24.935
 Low: $ 15.83 $ 14.56

Company Description (as filed with the SEC)

We are a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Leveraging our expertise in ophthalmology, gene therapy and drug development, we are developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases for which there are no currently approved treatments. Our lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase 3 clinical development in the first half of 2018 and represents the most clinically advanced product candidate for this indication worldwide. In data from 32 patients treated with NSR-REP1 across four open-label clinical trials, over 90% of treated patients maintained their visual acuity over a one-year follow-up period.  ... More ...  

Risk Grade

Where does NITE fit in the risk graph?

Risk Grade Scale

Nasdaq Official Price

Consensus Recommendation

Analyst Info